SuperHuman Fund I · Portfolio & Access Record Confidential · not an offer

Small checks. Elite rooms.

Active deployment began Nov ’25, so 8 of 9 checks are under 10 months old. This is a record of access and early momentum on $25–50k checks, not realized returns. Fund II scales the check ~10x to turn the same access into real ownership.

Capital leverage
151×
$350k of capital bought a seat in ~$53M of institutionally-underwritten rounds.
Combined ARR
$7M+
Disclosed revenue across the book, at pre-seed.
Tier-1 syndicate
8/9
Deals with a named institutional co-investor: a16z, Draper, Accel, Caffeinated, 1517, Mayo.
Portfolio: 9 companies
CompanySectorFounderCheck Total raisedHow we got inCo-investorsProgress since our check
HydraDAOSeed
Prior relationship
Organ replacement / immortality Kai Micah Mills
Thiel Fellow, 3x exited
$50k $4.1M
Bought secondaries after token dip; already knew founder Moonrock Capital Spinal cord fusion in live rats (subjects walked again)
ZaviaBioPre-seed
First check
Weed-resistant crops / food security Paz Alvarez
Obsessed storyteller + strong CSO
$25k $0.46M
First US institutional check into the company GRIDx Target protein −50% in greenhouse trial; seed in ~6 mos
Lume HealthPre-seed
Inbound
Continuous cortisol monitor Vicki Powell
ex-Apple wearables + Oxford
$50k $2.27M
Advised founder 6 mos before the round to earn allocation Oxford Seed Fund, Supermoon, Disrupt VC 1k pre-orders; <6% variability prototype
DognosisSeed
InboundCompetitive
Dog BCIs for cancer screening Akash Kulgod
Berkeley + IDF K9 unit
$25k $6.2M
In just before the round turned hot / oversubscribed BoostVC, Caffeinated, Draper, 1517, Accel India Marked up to $25M (from $15M); 90%+ accuracy, 25 pilot hospitals
Origin GenomicsSeed
First checkPrior relationship
Germline DNA editing in embryos Cathy Tie
Thiel Fellow, dropout, PR machine
$50k (unannounced) First check in the seed; already knew founder (unannounced) Recruited a world CRISPR pioneer; first-ever IRB approval for embryo editing
Kangaroo BioPre-seed
Competitive
Artificial wombs Landice Gao
YC + Stanford PhD
$50k $4.8M
Re-opened a closed pre-seed (after I introed founder to Nucleus CEO) Draper, Alumni Ventures, Halogen VC Endometrium alive 4 wks ex-body; monkey trials next
ElectrokarePre-seed
CompetitiveWarm intro
AI biomarker prediction Mitchell Leshchiner
21, first company at 12
$25k $2M
Into a closing round last-minute on a warm intro & value add a16z, Techstars, Mayo Clinic $2M ARR + Mayo Clinic partnership, all in <15 mos
HerasightSeed
Warm intro
Embryo selection Michael Christensen
Math dropout + quant
$50k $10M
In ahead of their first real institutional round; warm intro Tim Draper, Long Game VC $5M+ ARR on word-of-mouth; priced round in ~6 mos
Kadence BioSeries A
CompetitiveWarm intro
Sexual enhancement John Boghossian
Compass & Atai co-founder, MIT
$25k $23M
Warm intro into an oversubscribed round Apeiron Phase 2a clinical trial in progress
Total $350k $52.83M Sum of checks · total round volume accessed
Selectivity & signal
Tier-1 co-investors. A live markup within 4 months.
Same access, 10× the check in Fund II.
Confidential, for discussion purposes only. Not an offer to sell or a solicitation to buy any interest in the Fund. Any offer is made solely through the Fund’s Limited Partnership and Subscription Agreements, which control.